Opko Health Inc.
OPKOpko Health Inc. is a healthcare company specializing in the development of innovative diagnostics and pharmaceuticals. Founded in 2007, the company focuses on personalized medicine, providing diagnostic tests and treatments in areas such as oncology, neurology, and infectious diseases. Its portfolio includes bio-pharmaceutical products, laboratory services, and consumer health products aimed at improving patient outcomes through targeted healthcare solutions.
Company News
OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's pr...
OPKO Health and Entera Bio have expanded their collaboration to develop the first oral long-acting PTH analog for hypoparathyroidism treatment, aiming to file an IND application in late 2026. The companies will maintain equal 50/50 ownership and cost-sharing for this program. Additionally, they are advancing oral oxyntomodulin (dual GLP-1/glucago...
Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.
NextPlat Corp provides an update on its strategic progress across healthcare services, communications, and e-commerce channels, highlighting cost reduction efforts, new contracts, and technology investments aimed at driving growth and profitability.
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
